Pathkey.AI Takes Chipforge Into Its First Customer Test

Chipforge Moves From Development Towards Customer Use

Pathkey.AI Ltd (ASX:PKY) is taking its AI chip-design project into its first real customer test, with Chipforge’s initial commercial contract secured before the platform’s general release. The ten-week proof-of-value programme carries a fixed fee of US$50,000, and the company says the first phase has been delivered.

The next stage is less certain. Progress depends on the client’s readiness to integrate the work into its mechanical solution, meaning the contract is an early validation of the workflow rather than evidence of a recurring-revenue business. Pathkey says Chipforge’s immediate priorities are completing the initial release, testing it and beginning further customer work.

The platform is being built to connect hardware requirements, circuit-code generation, verification, error correction and implementation in one workflow. Its initial focus is field-programmable gate arrays, or FPGAs, while application-specific integrated circuits remain a separate longer-term stage of the roadmap. Development has also covered design records, reusable components, engineering-tool integration and testing on physical hardware.

Funding Extends the Commercialisation Push

The quarter included a $2.8 million strategic placement, leaving Pathkey with $5.83 million in cash and no debt at 30 September. The financing gives the company room to keep funding product development across both Chipforge and TrialKey, following the $2.8 million strategic placement that was reported alongside Sam Weiss’s appointment as a strategic advisor.

That balance came against operating cash use of $1.063 million for the quarter, with only $10,000 received from customers. The Appendix 4C reports estimated funding of 5.48 quarters based on the quarter’s operating cash outflow, although that is a mechanical runway estimate rather than a forecast of future spending or revenue. Cash receipts, customer conversion and development costs will determine how quickly that cushion changes.

TrialKey Expands Its Commercial Offer

Pathkey’s clinical-trial platform, TrialKey, broadened its offering beyond predictive assessment during the quarter. It can now assess early study concepts and confidential draft protocols, compare alternative designs within agreed study and budget constraints, benchmark comparable trials and produce indicative cost comparisons. Testing and client validation are continuing.

Business development activity has generated higher enquiry levels, with new client engagement anticipated in the December 2026 quarter. Those opportunities are not yet reported as signed or paid work. The commercial plan combines scoped assessments and design-support engagements for biotech sponsors with potential pilot licensing through contract research organisations, while the company cautions that TrialKey outputs do not establish treatment efficacy or guarantee trial success.

Technical Support Arrives Ahead of Launch

Chipforge’s commercialisation effort now has backing from an expanded team across Australia, Singapore and India, spanning software, AI and hardware engineering. Associate Professor Anupam Chattopadhyay, whose appointment added formal chip-design and AI expertise to the new advisory structure, had already been involved in developing and testing the early-stage technology. The company also appointed former Altium chair Sam Weiss as a strategic advisor.

The important test from here is not another product description but evidence of use: whether the first proof-of-value progresses, whether additional Chipforge customers pay for projects, and whether TrialKey’s current enquiries convert into revenue. Pathkey has built a larger technical and financial platform for that test, but the September quarter still shows a business before scale rather than one operating at scale.